Abpro Holdings (ABPO) Research & Development (2024 - 2026)
Abpro Holdings' (ABPO) quarterly Research & Development came in at $13000.0 in Q1 2026, down 96.0% YoY from $325000.0 in Q1 2025, and down 87.96% on a QoQ basis from $108000.0 in Q4 2025.
Abpro Holdings (ABPO) Research & Development (2024 - 2026) Analysis & Trends
Abpro Holdings (ABPO) has 3 years of Research & Development data on file, last reported at $13000.0 in Q1 2026.
- Quarterly Research & Development fell 96.0% year-over-year to $13000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $677000.0 (down 70.67% YoY) and the FY2025 annual result came in at $989000.0, down 66.85% from the prior year.
- Research & Development declined to $13000.0 in Q1 2026, from $108000.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $1.0 million in Q1 2024 to a low of $13000.0 in Q1 2026.
- A 3-year average of $442777.8 and a median of $325000.0 in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2025 — Research & Development tumbled 62.15% — and 2026, when it tumbled 96.0%.
- Tracing ABPO's Research & Development over 3 years: stood at $514000.0 in 2024, then sank by 78.99% to $108000.0 in 2025, then plunged by 87.96% to $13000.0 in 2026.
- The last three Research & Development figures came in at $13000.0 (Q1 2026), $108000.0 (Q4 2025), and $243000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - | 9,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13,000.00 |
| Dec 31, 2025 | 108,000.00 |
| Sep 30, 2025 | 243,000.00 |
| Jun 30, 2025 | 313,000.00 |
| Mar 31, 2025 | 325,000.00 |
| Dec 31, 2024 | 514,000.00 |
| Sep 30, 2024 | 642,000.00 |
| Jun 30, 2024 | 827,000.00 |
| Mar 31, 2024 | 1.00 Mn |